NATCO Pharma Limited (NATCOPHARM) Stock Statistics & Valuation Metrics

NATCO Pharma Limited has a market cap or net worth of ₹182.75B. The enterprise value is ₹162.22B.

NATCO Pharma Limited has 179,109,860 shares outstanding. The number of shares has decreased by -2.65% in one year.

NATCO Pharma Limited’s return on equity (ROE) is 0.25 and return on invested capital (ROIC) is 20.24%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, NATCO Pharma Limited had revenue of 44.30B and earned 18.85B in profits. Earnings per share was 105.26.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

NATCO Pharma Limited pays an annual dividend of ₹6, resulting in a dividend yield of 0.59%

NATCO Pharma Limited upcoming earnings date is Aug 6, 2025, TBA (Confirmed).

NATCO Pharma Limited as a current ratio of 5.59, with Debt / Equity ratio of 3.67%

In the past 12 months, NATCO Pharma Limited has paid 4.08B in taxes.

NATCO Pharma Limited EV to EBITDA ratio is -0.74, with an EV/FCF ratio of -1.33.

NATCO Pharma Limited has ₹24.63B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹24.63B billion.

Gross margin is 74.41%, with operating margin of 44.27%, and net profit margin of 42.56%.

The average price target for NATCO Pharma Limited is ₹1,006.50, which is 11.43% higher than the current price. The consensus rating is Hold